VEDANTA BIOSCIENCES INC.

Company Overview

Vedanta Biosciences was launched by PureTech Health and other founders with a foundational understanding of the role of gut bacteria and its role in inflammation and disease. Vedanta Biosciences’ cofounder Kenya Honda, along with others, studied commensal bacteria, finding it capable of inducing regulatory T cells and offering new avenues of disease treatment via microbiome modulation.

Vedanta Biosciences developed a discovery and development platform for the design and manufacture of LBPs, mainly belonging to several species of bacteria in Clostridium Clusters IV and XIVa. Using translational medicine approaches and mechanistic studies, Vedanta Biosciences constructed a proprietary strain library from healthy, well-validated subjects from across the globe. These strains are modified to introduce pharmacologically-relevant properties, like the ability to induce distinct immune responses. Once the strains are optimized, these are combined into consortia using proprietary bioinformatic tools and mathematical modeling. Vedanta Biosciences has a fully-equipped facility to manage banking, fermentation, separation, lyophilization and formulation of bacterial drug products.

Vedanta Biosciences has a number of collaborations and partnership agreements with clinical and academic institutions to advance the understanding of the microbiome and develop microbiome drugs. It collaborated with Bristol Myers Squibb for the clinical candidate VE800 for application in immune-oncology. Additionally, Vedanta Biosciences was awarded two research grants from CARB-X to support the development of VE303 for the treatment of high-risk CDI and VE707 for the prevention of infection and recurrence of several MDROs.

In June 2020, Vedanta Biosciences announced positive topline data from two Phase 1 studies in healthy volunteers of VE202, the drug candidate for IBD. The study showed that the candidate was generally safe and well tolerated at all doses and demonstrated durable and dose-dependent colonization.

Vedanta Biosciences declared, in April 2022, that the findings from a Phase 1a/1b research assessing the safety, tolerability and colonization dynamics of VE303 in healthy individuals would be published in the journal Cell Host & Microbe. VE303 is a candidate for a first-in-class specified bacterial consortium that may prevent recurring infections with Clostridium difficile (CDI). In podium presentations at Digestive Illness Week in May 2022, the business will offer three research updates related to its VE303 and VE202 (for inflammatory bowel disease) initiatives.

Company's Business Segments

• Products : VE202, VE303, VE707, Others
• Services : Research and Development, Tests, Partnerships, Others